HSE Grants Hospital Pricing Approval for EYLEA® 8mg for Wet AMD and Diabetic Macular Oedema in Ireland
Bayer has announced that the HSE has granted hospital pricing approval for EYLEA® 8mg for eligible adult patients with wet age-related macular degeneration and diabetic macular oedema in Ireland.
Bayer is pleased to announce that the HSE has granted hospital pricing approval for EYLEA® (aflibercept) 114.3 mg/mL solution for injection in a pre-filled syringe. This is indicated for the treatment of adult patients with neovascular (wet) age-related macular degeneration (nAMD) and adult patients with visual impairment due to diabetic macular oedema (DMO), both on the basis that aflibercept is used as a second-line treatment, following first-line treatment with bevacizumab.
Dr Tristan Cooper, Medical Director, Bayer Ireland, said: “EYLEA 8mg offers a higherdose aflibercept option that may help maintain vision outcomes for appropriate patients while enabling longer intervals between injections for some individuals, reducing treatment and clinic visit burden over time.”1,2
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
